Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5974 USD | -2.80% | +5.19% | +9.96% |
May. 09 | Transcript : Sangamo Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (SGMO) SANGAMO THERAPEUTICS Reports Q1 Revenue $481,000 | MT |
Evolution of the average Target Price on Sangamo Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Sangamo Therapeutics, Inc.
Truist Securities | |
HC Wainwright | |
Wells Fargo Securities | |
Wedbush | |
RBC Capital Markets | |
Barclays | |
Stifel Nicolaus |
EPS Revisions
- Stock Market
- Equities
- SGMO Stock
- Consensus Sangamo Therapeutics, Inc.